Fifty 1 Labs, Inc. Stock

FITY

US2104931025

Biotechnology & Medical Research

Market Closed - OTC Markets 18:41:41 29/05/2026 +04			5-day change	1st Jan Change
0.000400 ^USD	+33.33%		+100.00%	-20.00%

08-26	Fifty 1 Labs, Inc. acquired Musculoskeletal Recovery Product Line of MSK Signal.	CI
08-10	Fifty 1 Labs, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026	CI

Latest news: Fifty 1 Labs, Inc.

08-26	Fifty 1 Labs, Inc. acquired Musculoskeletal Recovery Product Line of MSK Signal.	CI
08-10	Fifty 1 Labs, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026	CI
08-10	Fifty 1 Labs, Inc. Reports Earnings Results for the Full Year Ended June 30, 2025	CI
01-05	Fifty 1 Labs, Inc. Announces CEO Changes	CI
14/08/25	Fifty 1 Labs, Inc. Announces the Completion of the Largest and Most Comprehensive Study of Sickle Cell Disease	CI
10/07/25	Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling 50 1 Labs, Inc. Toward $50 Million Valuation	CI
30/04/25	Fifty 1 Labs, Inc. Appoints Michael Lawson as Chairman of the Board	CI
30/04/25	Fifty 1 Labs, Inc. Appoints Michael Lawson as Chief Executive Officer	CI
30/04/25	The Fifty 1 Labs Biosentry Division Will Develop State-Of-The-Art Biohazard Sensing Sensors Capable of Detecting Pathogens	CI
30/04/25	UAV Corp. Announces Strategic Partnership with 50 1 Labs, Inc	CI
08/04/25	Uav Corp And Genetic Networks Announce Strategic Collaboration	RE
20/03/25	Fifty 1 Labs, Inc. Appoints Gennaro D'Urso as CEO	CI
20/03/25	Fifty 1 Labs, Inc. Appoints Gennaro D'urso as Chairman	CI

More news

Press Releases: Fifty 1 Labs, Inc.

08-26	Fifty 1 Labs, Inc. Acquires MSK Signal Recovery Product Line to Accelerate Growth in the Peptide and Musculoskeletal Health Market	AQ
08-07	Fifty 1 Labs Outlines Planned U.S. Telehealth Peptide Services Platform	AQ
07-10	Fifty 1 Labs Announces Strategic Evolution into Peptide Biotechnology and Telehealth	AQ
04-15	Fifty 1 Labs, Inc. Accelerates Peptide Biotechnology Push into Musculoskeletal Health	AQ
04-14	Fifty 1 Labs, Inc. Eliminates 612 Million Shares from the Market	AQ

More press releases

Managers and Directors: Fifty 1 Labs, Inc.

Manager	Title	Age	Since
Pritpaul Singh Arora CEO	Chief Executive Officer	47	-
Brandon Spikes PSD	President	-	-
Alind Gupta CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Robert Clark BRD	Director/Board Member	49	30/04/2025
Brandon Spikes CHM	Chairman	-	12/07/2023
Curtis Young BRD	Director/Board Member	-	-

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FIFTY 1 LABS, INC.	+33.33%	+100.00%	-85.71%	-97.78%	237K
LONZA GROUP AG	+0.22%	+0.07%	-1.90%	+8.24%	45.81B
IQVIA HOLDINGS INC.	-0.32%	+4.61%	+43.90%	+26.98%	44.39B
REVOLUTION MEDICINES, INC.	-4.36%	-5.66%	+338.30%	+516.88%	43.91B
BEONE MEDICINES AG	+0.46%	-0.83%	+6.38%	+73.76%	39.4B
CELLTRION, INC.	-0.17%	-3.22%	+10.29%	+38.69%	31.26B
MEDPACE HOLDINGS, INC.	-0.65%	+5.14%	+25.61%	+120.17%	17.32B
ASCENDIS PHARMA A/S	+3.30%	-5.03%	-	-	15.75B
EUROFINS SCIENTIFIC SE	+1.66%	+5.30%	+19.25%	+34.93%	14.73B
ICON PUBLIC LIMITED COMPANY	+0.86%	+9.05%	+0.47%	-33.54%	13.31B
Average	+3.43%	+0.34%	+39.62%	+76.48%	26.59B
Weighted average by Cap.	-0.40%	-0.28%	+72.06%	+122.09%

See all sector performances

Fifty 1 Labs, Inc. is a biotechnology and life sciences company. The Company focuses on peptide products, peptide discovery, AI-enabled research, and clinical development. It also focuses on peptide science, musculoskeletal health, sports performance, injury recovery, rehabilitation, and evidence-driven wellness. It owns 51, LLC, its sports nutrition subsidiary offering a premium line of supplements including pre-workout formulas, BCAAs, ION+ Electrolyte Formula, Turmeric Gummies, and Ashwagandha Gummies designed to enhance athletic performance, recovery, and overall health. It has acquired a musculoskeletal recovery product line. The product line includes five key product concepts designed to support the Company's peptide and musculoskeletal health markets. The portfolio includes natural health products focused on connective tissue recovery, inflammation support, post-surgical recovery nutrition, joint and cartilage support, and an investigational BPC-157-focused research platform.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
16/09/26	$0.000200	-.--%	24,055,460
15/09/26	$0.000200	-.--%	13,051,573
14/09/26	$0.000200	-.--%	2,511,500
11/09/26	$0.000200	-.--%	325,001
10/09/26	$0.000200	-.--%	10,346,000

Real-time OTC Markets

More quotes

Stock Market
Stocks
FITY Stock

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!

SEIZE THE OFFER!

Market Cap	281K 244K 231K 209K 392K 27M 395K 2.75M 1.06M 13.7M 1.06M 1.03M 43.66M	P/E 2009	-0.05x	P/E 2010	-0.01x
Enterprise Value	12.55M 10.88M 10.28M 9.34M 17.5M 1.2B 17.6M 123M 47.44M 611M 47.16M 46.11M 1.95B	EV / Sales 2009	1.86x	EV / Sales 2010	2.41x
Free-Float	57.9%	Yield 2009 *	-	Yield 2010	-

1 week	0		0
1 month	0		0
Current year	0		0
1 year	0		0
3 years	0		0.05
5 years	0		0.2
10 years	0		0.23

	2009	2010
Net sales	5.41M 4.69M 4.43M 4.02M 7.54M 519M 7.59M 52.92M 20.45M 263M 20.33M 19.88M 839M	5.11M 4.43M 4.18M 3.8M 7.12M 490M 7.16M 49.93M 19.29M 248M 19.18M 18.76M 792M
Net income	-2.23M -1.93M -1.83M -1.66M -3.11M -214M -3.13M -21.82M -8.43M -109M -8.38M -8.2M -346M	-1.89M -1.64M -1.55M -1.41M -2.64M -182M -2.66M -18.52M -7.16M -92.17M -7.12M -6.96M -294M
Net Debt	9.96M 8.63M 8.15M 7.4M 13.87M 955M 13.96M 97.35M 37.62M 484M 37.4M 36.57M 1.54B	12.27M 10.64M 10.05M 9.13M 17.1M 1.18B 17.21M 120M 46.37M 597M 46.1M 45.08M 1.9B

Fifty 1 Labs, Inc. Stock

Stocks

FITY

US2104931025

Biotechnology & Medical Research

Valuation: Fifty 1 Labs, Inc.

Chart: Fifty 1 Labs, Inc.

Latest news: Fifty 1 Labs, Inc.

Press Releases: Fifty 1 Labs, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Fifty 1 Labs, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 day	+33.33%
1 week	+100.00%
Current month	+100.00%
1 month	+33.33%
3 months	-20.00%
Current year	-20.00%